A computational approach to finding novel targets for existing drugs

PLoS Computational Biology

Volumn 7, Issue 9, 2011, Pages

  Li, Yvonne Y ^a   An, Jianghong ^a   Jones, Steven J M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSIFICATION (OF INFORMATION); DRUG INTERACTIONS; MOLECULES; PROTEINS;

COMPUTATIONAL APPROACH; DRUG DISCOVERY; DRUG REPOSITIONING; DRUG TARGETS; DRUG-TARGET INTERACTIONS; LARGE-SCALES; PROTEIN DRUGS; SMALL-MOLECULE DRUGS; STRINGENTS; THERAPEUTIC USE;

DISEASES;

BECOCALCIDIOL; DASATINIB; ELDECALCITOL; GEFITINIB; GENISTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 14; NILOTINIB; PIPENDOXIFENE; QUERCETIN; SORAFENIB; VATALANIB; ZAFIRLUKAST; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; DRUG; PROTEIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE;

ARTICLE; ASTHMA; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IC 50; IN VITRO STUDY; INFLAMMATORY DISEASE; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PROTEIN BINDING; PROTEIN DATABASE; REPRODUCIBILITY;

COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEINS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; TOSYL COMPOUNDS;

EID: 80053453210     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002139     Document Type: Article

References (66)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge Nature Reviews Drug Discovery. 10.1038/nrd3078. Available: http://www.nature.com/nrd/current_issue/ via the Internet.
2. Lawrence S, (2007) Drug output slows in 2006. Nat Biotechnol 25: 1073 10.1038/nbt1007-1073. 12/10/2007.
3. Ashburn TT, Thor KB, (2004) Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683 10.1038/nrd1468. 12/10/2007.
4. Druker B, (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30.
5. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132 10.1038/nbt1358.
6. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 10.1038/ng.518. Available: www.refworks.com via the Internet.
7. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719-2729 10.1056/NEJMoa0902542.
8. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, et al. (2009) Drug discovery using chemical systems biology: Repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 5: e1000423 10.1371/journal.pcbi.1000423.
9. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181 10.1038/nature08506.
10. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263-266 10.1126/science.1158140.
11. Jorgensen WL, (2004) The many roles of computation in drug discovery. Science 303: 1813-1818 10.1126/science.1096361. 12/10/2007.
12. Abagyan R, Totrov M, (2001) High-throughput docking for lead generation. Curr Opin Chem Biol 5: 375-382.
13. Abagyan R, Totrov M, Kuznetsov D, (1994) ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem 15: 488 10.1002/jcc.540150503. 12/10/2007.
14. Abagyan R, Orry A, Raush E, Budagyan L, Totrov M, (2007) ICM manual. version 3.0.
15. Cavasotto CN, Ortiz MA, Abagyan RA, Piedrafita FJ, (2006) In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Bioorg Med Chem Lett 16: 1969-1974 10.1016/j.bmcl.2005.12.067.
16. Jain AN, (2009) Effects of protein conformation in docking: Improved pose prediction through protein pocket adaptation. J Comput Aided Mol Des 23: 355-374 10.1007/s10822-009-9266-3.
17. Kumar S, Boehm J, Lee JC, (2003) p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726 10.1038/nrd1177.
18. Verdonk ML, Mortenson PN, Hall RJ, Hartshorn MJ, Murray CW, (2008) Protein-ligand docking against non-native protein conformers. J Chem Inf Model 48: 2214-2225 10.1021/ci8002254.
19. Huang N, Shoichet BK, Irwin JJ, (2006) Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801 10.1021/jm0608356.
20. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063 10.1182/blood-2007-07-102061.
21. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, et al. (2010) Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 49: 3611-3618 10.1021/bi100070r.
22. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, et al. (2005) Cellular targets of gefitinib. Cancer Res 65: 379-382.
23. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, et al. (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804: 445-453 10.1016/j.bbapap.2009.11.008.
24. Ghoreschi K, Laurence A, O'Shea JJ, (2009) Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol 10: 356-360 10.1038/ni.1701.
25. Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, et al. (2007) Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 17: 306-310 10.1007/s10165-007-0592-9.
26. Eklund KK, Lindstedt K, Sandler C, Kovanen PT, Laasonen L, et al. (2008) Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol 14: 294-296 10.1097/RHU.0b013e318188b1ce.
27. Vernon MR, Pearson L, Atallah E, (2009) Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol 15: 267 10.1097/RHU.0b013e3181b0d352.
28. Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, et al. (2010) Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol 10.1007/s10165-010-0392-5.
29. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
30. Komander D, Kular GS, Schuttelkopf AW, Deak M, Prakash KR, et al. (2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 12: 215-226 10.1016/j.str.2004.01.005.
31. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, et al. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 104: 20523-20528 10.1073/pnas.0708800104.
32. Cotreau MM, Stonis L, Dykstra KH, Gandhi T, Gutierrez M, et al. (2002) Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. J Clin Pharmacol 42: 157-165.
33. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
34. Naldi L, Raho G, (2009) Emerging drugs for psoriasis. Expert Opin Emerg Drugs 14: 145-163 10.1517/14728210902771334.
35. Pinette KV, Yee YK, Amegadzie BY, Nagpal S, (2003) Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3: 193-204.
36. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH, (1996) The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 54: 243-251.
37. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189.
38. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell 7: 129-141 10.1016/j.ccr.2005.01.007.
39. Balendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, et al. (2000) Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem 275: 27045-27054 10.1074/jbc.M003001200.
40. Belayev L, Marcheselli VL, Khoutorova L, Rodriguez de Turco EB, Busto R, et al. (2005) Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 36: 118-123 10.1161/01.STR.0000149620.74770.2e.
41. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336 10.1038/nbt1068.
42. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044 10.1038/nbt1328.
43. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, et al. (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 7: 3490-3498 10.1158/1535-7163.MCT-08-0826.
44. Kolb P, Ferreira RS, Irwin JJ, Shoichet BK, (2009) Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol 20: 429-436 10.1016/j.copbio.2009.08.003.
45. Sabio M, Jones K, Topiol S, (2008) Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. part 2: Identification of active compounds. Bioorg Med Chem Lett 18: 5391-5395 10.1016/j.bmcl.2008.09.046.
46. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. (2006) DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668-72 10.1093/nar/gkj067.
47. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370 12/10/2007.
48. An J, Totrov M, Abagyan R, (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4: 752-761 10.1074/mcp.M400159-MCP200. 12/10/2007.
49. Raevsky OA, Trepalin SV, Trepalina HP, Gerasimenko VA, Raevskja OE, (2002) SLIPPER-2001 - software for predicting molecular properties on the basis of physicochemical descriptors and structural similarity. J Chem Inf Comput Sci 42: 540-549.
50. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
51. UniProt Consortium (2010) The universal protein resource (UniProt) in 2010. Nucleic Acids Res 38: D142-8 10.1093/nar/gkp846.
52. Choi YH, Yoon CJ, Park JH, Chung JW, Kwon JW, et al. (2003) Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: Its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J Radiol 4: 109-116.
53. Thomas CC, Deak M, Alessi DR, van Aalten DM, (2002) High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 12: 1256-1262.
54. Fukuda M, Kojima T, Kabayama H, Mikoshiba K, (1996) Mutation of the pleckstrin homology domain of bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem 271: 30303-30306.
55. Bando S, Takano T, Yubisui T, Shirabe K, Takeshita M, et al. (2004) Structure of human erythrocyte NADH-cytochrome b5 reductase. Acta Crystallogr D Biol Crystallogr 60: 1929-1934 10.1107/S0907444904020645.
56. Stankova J, Lawrance AK, Rozen R, (2008) Methylenetetrahydrofolate reductase (MTHFR): A novel target for cancer therapy. Curr Pharm Des 14: 1143-1150.
57. Greasley SE, Marsilje TH, Cai H, Baker S, Benkovic SJ, et al. (2001) Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase. Biochemistry 40: 13538-13547.
58. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336 10.1038/nbt1068.
59. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, et al. (2010) Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 49: 3611-3618 10.1021/bi100070r.
60. Oelkers W, (2004) Drospirenone, a progestogen with antimineralocorticoid properties: A short review. Mol Cell Endocrinol 217: 255-261 10.1016/j.mce.2003.10.030.
61. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, et al. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270: 23975-23983.
62. Lebovitz H, (2006) Diabetes: Assessing the pipeline. Atheroscler Suppl 7 pp. 43-49 10.1016/j.atherosclerosissup.2006.01.007.
63. Klaholz BP, Mitschler A, Moras D, (2000) Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J Mol Biol 302: 155-170 10.1006/jmbi.2000.4032.
64. Desai SH, Boskovic G, Eastham L, Dawson M, Niles RM, (2000) Effect of receptor-selective retinoids on growth and differentiation pathways in mouse melanoma cells. Biochem Pharmacol 59: 1265-1275.
65. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, et al. (1996) 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271: 22441-22446.
66. Lengqvist J, Mata De Urquiza A, Bergman AC, Willson TM, Sjovall J, et al. (2004) Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol Cell Proteomics 3: 692-703 10.1074/mcp.M400003-MCP200.